Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug 30;11(10):338.
doi: 10.21037/atm-23-1550. Epub 2023 Jun 27.

Neoadjuvant immunotherapy in early-stage triple negative breast cancer

Panayiotis Laouris  1 , Mariana Espirito Santo Rodrigues  1 , Susanne Crocamo Ventilary Costa  1 , Bruno Henrique Rala de Paula  1
Affiliations
Editorial

Neoadjuvant immunotherapy in early-stage triple negative breast cancer

Panayiotis Laouris et al. Ann Transl Med. .
No abstract available

Keywords: HER2-negative breast cancer; Neoadjuvant immunotherapy; pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA-MSHA); triple-negative breast cancer (TNBC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-1550/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33. 10.3322/caac.21708 - DOI - PubMed
    1. Loibl S, Poortmans P, Morrow M, et al. Breast cancer. Lancet 2021;397:1750-69. 10.1016/S0140-6736(20)32381-3 - DOI - PubMed
    1. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-23. 10.1093/annonc/mdt303 - DOI - PMC - PubMed
    1. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018;19:40-50. 10.1016/S1470-2045(17)30904-X - DOI - PubMed
    1. Potter DA, Herrera-Ponzanelli CA, Hinojosa D, et al. Recent advances in neoadjuvant therapy for breast cancer. Fac Rev 2021;10:2. 10.12703/r/10-2 - DOI - PMC - PubMed